Holen Sie sich die Stockscreener-App
111.12
2.33%
2.53
Handel nachbörslich:
111.60
0.48
+0.43%
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed | 10/1/26 - ktnv.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
3 AI Healthcare Stocks With At Least 8% Revenue Growth - Simply Wall Street
Insmed Price Target Cut to $207.00/Share From $237.00 by Barclays - Moomoo
EMBARC and Insmed plan study to evaluate brensocatib in bronchiectasis - scanx.trade
Net income before discontinued operations of Insmed Incorporated – HAN:IM8N - TradingView
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - uk.finance.yahoo.com
Insmed shares deliver 41.43% annualized return over five years - scanx.trade
Insmed TPIP shows sustained improvement in PAH study - scanx.trade
BMO Capital initiates coverage on Insmed with Outperform rating - scanx.trade
Insmed 15-year return: $1,000 investment grows to $27,361 - scanx.trade
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Benzinga
3 Healthcare Stocks Showing Why the Sector Still Has Momentum - MarketBeat
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? - Yahoo Finance
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Why Insmed (INSM) Stock Is Down Today - Quiver Quantitative
2 New Jersey companies named top places to work for 2026. Here's where - Asbury Park Press
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Goldman Sachs Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $188 - moomoo.com
Insmed Incorporated (INSM) latest stock news and headlines - Yahoo Finance UK
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - Yahoo Finance
FDA priority review for Insmed's Arikayce sNDA - thepharmaletter.com
Insmed Says FDA Grants Priority Review to Arikayce Supplemental Filing for MAC Lung Disease - Yahoo Finance
Why is Insmed stock climbing today? By Investing.com - Investing.com Canada
Insmed stock rises on FDA priority review for Arikayce By Investing.com - Investing.com Canada
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants priority review for Insmed’s ARIKAYCE lung disease drug By Investing.com - Investing.com Canada
INSM Looks 44.7% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
A lung-disease drug may reach patients earlier. Insmed gets FDA priority review. - Stock Titan
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Insmed (INSM) Fully Priced After Its 296% Revenue Surge? - webull.com
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
1INSM.MI Interactive Stock Chart | INSMED INC Stock - Yahoo Finance
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026 - Kalkine Media
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Insmed at Cantor conference: higher sales outlook lifts growth case By Investing.com - Investing.com Australia
Why Insmed (INSM) Stock Is Up Today - Quiver Quantitative
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity (NASDAQ:INSM) - Seeking Alpha
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):